Clinical Trial Update: Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab and tremelimumab with or without capecitabine as adjuvant therapy for biliary tract cancers; the study status is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Distal Cholangiocarcinoma
• Gallbladder Cancer
• Hilar Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Durva (Durvalumab)
• Treme (tremelimumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma | Phase 2 | Status: COMPLETED